Is BPC-157 Legal in Maryland? What Women Need to Know Before Ordering

What BPC-157 Actually Is (and Why Women Are Looking for It)

BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. It consists of 15 amino acids and does not occur naturally in this exact sequence in the human body. Researchers have studied it in rodent models for tissue repair, gut healing, tendon recovery, and neurological protection.

Women seeking BPC-157 in Maryland tend to fall into a few distinct groups. Those in their reproductive years often come to it after a sports injury, pelvic surgery, or an inflammatory bowel flare. Women in perimenopause and post-menopause search for it in the context of joint pain and slower healing, both of which accelerate after estrogen declines. Women with PCOS are another common group, drawn to online communities that discuss gut permeability and systemic inflammation in that condition.

The appeal is understandable. What matters, though, is whether you can obtain it legally in Maryland, and whether the evidence supports the risk.

The Evidence Gap You Deserve to Hear

Most published BPC-157 research is conducted in rats or mice. A 2018 review in the journal Current Pharmaceutical Design compiled animal data showing accelerated tendon-to-bone healing and gastroprotective effects, but acknowledged the near-complete absence of controlled human trials [reviewed in the context of FDA's 2023 bulk-substances decision at fda.gov]. No Phase III randomized controlled trial in women, or in humans generally, has been published as of this writing.

Women have been historically under-represented in clinical research, and peptide research is no exception. The animal data cannot be extrapolated to female physiology with any confidence, particularly given that estrogen, progesterone, and the menstrual cycle modify tissue repair rates, gut permeability, and inflammatory signaling in ways that rodent models do not replicate. That is not a reason to dismiss interest in BPC-157. It is a reason to hold the evidence lightly.

The Federal Legal Framework: FDA, Compounding, and the Bulks List

BPC-157 is not FDA-approved as a drug product. That single fact shapes everything else about its legal status.

What "Not FDA-Approved" Means for Compounding

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare drugs from bulk active pharmaceutical ingredients (APIs) under specific conditions. Section 503A governs traditional compounding pharmacies that fill individual prescriptions. Section 503B governs outsourcing facilities that produce larger batches. Both sections allow bulk compounding only from substances on an approved list or under specific conditions set by the FDA.

In 2023, the FDA evaluated BPC-157 under its bulk-substances nomination process and placed it on the list of substances that may not be used in compounding because the agency determined that using it in compounding raises concerns about safety, or that it is not an appropriate candidate based on available evidence. This is a federal determination that applies in all 50 states, including Maryland.

What the FDA Restriction Actually Prohibits

The restriction means that a 503A pharmacy filling your individual prescription, and a 503B outsourcing facility producing batches, cannot legally use BPC-157 as a bulk API. Pharmacies that continue to compound and sell it are operating outside FDA compliance. This does not automatically create a Maryland criminal charge for the patient. However, the product entering interstate commerce under these conditions is not legally manufactured under federal standards.

Vendors selling BPC-157 labeled "for research use only" or "not for human use" are attempting to sidestep the FDA drug framework. Purchasing and self-administering such a product may not trigger a Maryland state criminal charge against you personally, but you have no assurance of purity, sterility, or actual peptide concentration in those products.

The Research Chemical Gray Zone

The phrase "research chemical" has no formal FDA regulatory category. It is a commercial label, not a legal status. FDA guidance is clear that marketing a substance for human consumption that has not been approved, or that bypasses the new drug application process, violates federal law regardless of how the product is labeled. Whether federal authorities choose to pursue any given transaction is a separate question from whether that transaction is legally compliant.

Maryland State Law: What the State Does (and Does Not) Add

Maryland has no statute that specifically names BPC-157. There is no Maryland law that independently bans it, nor is there a state law that independently legalizes it. The legal framework in Maryland for obtaining any compounded drug, including a peptide, runs through:

1. The Maryland Board of Pharmacy, which licenses and regulates pharmacies operating in the state.
2. The Maryland Medical Practice Act, which governs what licensed prescribers can lawfully prescribe.
3. Federal law, which preempts state law in the compounding context under the Drug Quality and Security Act of 2013.

A Maryland-licensed physician or nurse practitioner can write a prescription for a compounded substance. The compounder receiving that prescription must comply with federal compounding law, including the FDA bulks-list restrictions. So even if your Maryland provider writes you a prescription in good faith, a compliant compounding pharmacy cannot legally fill it for BPC-157 under current federal rules.

Maryland Board of Pharmacy Compliance

The Maryland Board of Pharmacy requires that compounding pharmacies operating in the state comply with USP standards and federal law. A pharmacy that compounds BPC-157 in Maryland and dispenses it to patients is doing so outside those requirements. Patients are not typically prosecuted, but they absorb the full risk of an unregulated product.

How to Get BPC-157 in Maryland: The Honest Options

Given the federal restriction, here is what the actual field looks like for a Maryland woman today.

Option 1: A Compliant Telehealth or Clinic Provider (Limited)

Some telehealth and integrative medicine providers continue to prescribe BPC-157 and refer patients to compounders. Those compounders are operating outside FDA compliance for this specific peptide. Whether you choose to proceed with that is a personal and medical decision. The honest framing is that you are using a product that has not been manufactured under FDA-compliant conditions, and you should factor that into your risk assessment.

Option 2: Research-Use Vendors (Not Recommended for Human Use)

Online vendors selling BPC-157 labeled "research use only" are widely accessible. Independent laboratory testing of such products, summarized in a 2022 analysis by the Journal of the American Medical Association on compounded peptides, found significant variation in peptide concentration and contamination risk in products purchased outside regulated compounding [see related FDA communication at fda.gov]. Using these products carries infectious risk from non-sterile preparation, unknown dosing, and zero recourse if something goes wrong.

Option 3: Clinical Trial Enrollment

If you are interested in BPC-157 for a specific condition, checking clinicaltrials.gov for open trials is a legitimate path. You would receive a monitored, regulated product, contribute to the evidence base, and have access to clinical oversight. As of early 2025, active human trials remain sparse.

A decision framework for Maryland women considering BPC-157:

| Your Situation | Recommended Path | |---|---| | Post-surgical recovery, want tissue support | Ask your surgeon about approved options; discuss PT and nutrition first | | Gut healing, IBD or IBS | GI referral; discuss LDN, dietary intervention, or approved biologics | | Perimenopause, joint pain | Rule out estrogen deficiency first; discuss HRT with your provider | | PCOS, inflammation | Evidence-based interventions include metformin, inositol, anti-inflammatory diet | | Genuinely want BPC-157 | Find a provider who prescribes it, understand the compliance gap, insist on a Certificate of Analysis from the compounder |

Sex-Specific Physiology: How Being a Woman Changes the BPC-157 Picture

No human pharmacokinetic data exists for BPC-157 in women or men. What follows is extrapolated from general peptide pharmacology and known sex differences in drug metabolism.

Menstrual Cycle Effects

Peptide absorption and tissue distribution can shift across the menstrual cycle. Estrogen upregulates growth factor receptors and modifies inflammatory cytokine profiles, meaning the theoretical tissue-repair effects of BPC-157 might differ between the follicular and luteal phases. No study has examined this. If you are tracking symptoms on any peptide therapy, logging cycle day alongside your notes is a reasonable practice.

Perimenopause and Post-Menopause

Estrogen loss after menopause accelerates collagen degradation, slows tendon healing, and increases gut permeability. Women in this life stage are particularly drawn to peptide therapies for these reasons. The irony is that the hormonal changes of menopause are well-understood, and hormone therapy, when appropriate, has documented effects on collagen synthesis and musculoskeletal health that BPC-157 has never been shown to match in humans. Estrogen therapy's collagen benefits are supported by actual human trials; BPC-157's are not.

The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy notes that systemic estrogen has favorable effects on skin, connective tissue, and musculoskeletal symptoms in symptomatic postmenopausal women. That evidence base is orders of magnitude stronger than anything available for BPC-157.

PCOS

Women with PCOS have altered gut microbiome composition, elevated systemic inflammation, and higher rates of leaky gut compared to women without PCOS, according to a 2021 review in Frontiers in Endocrinology. BPC-157's proposed mechanism of gut healing draws some women with PCOS toward it. However, insulin resistance management, androgen normalization, and dietary intervention have actual human evidence for gut and inflammatory improvement in PCOS. BPC-157 does not.

Autoimmune Conditions

Women account for approximately 80% of autoimmune disease diagnoses in the United States, according to NIH estimates. Some women with lupus, Hashimoto's thyroiditis, or rheumatoid arthritis seek BPC-157 for its proposed anti-inflammatory and tissue-repair properties. Peptides can, in theory, modulate immune signaling. In practice, no human trial has examined BPC-157 in an autoimmune population, and peptides that modulate immune response carry the theoretical risk of exacerbating autoimmunity in susceptible individuals. Discuss this with your rheumatologist or endocrinologist before proceeding.

Pregnancy, Lactation, and Contraception: The Required Safety Section

If you are pregnant, trying to conceive, or breastfeeding, do not use BPC-157.

This is not a precautionary hedge. It is a direct statement based on the absence of any human safety data in pregnancy or lactation, combined with the fact that injectable peptides can cross biological barriers and may affect fetal development in ways that have not been studied.

Pregnancy

BPC-157 has no FDA pregnancy category because it has never been approved as a drug. No human pregnancy data exists. Animal teratogenicity studies, which are a standard requirement before any substance is used in pregnant women, have not been published in peer-reviewed literature for BPC-157. The FDA's position on BPC-157 in compounding already reflects inadequate safety evidence for the general population. Pregnancy safety is entirely unknown.

If you are using BPC-157 and become pregnant, stop immediately and contact your OB-GYN or midwife.

Lactation

No lactation pharmacokinetic data exists for BPC-157. Peptides vary widely in their transfer into breast milk and their oral bioavailability in an infant. Because BPC-157 is typically injected, any transfer into breast milk would then be taken orally by the nursing infant, which reduces systemic absorption due to gastric digestion. However, some peptides do survive partial digestion, and the complete absence of data means the risk to a nursing infant is unknown, not zero. The conservative recommendation is to avoid BPC-157 while breastfeeding.

Contraception

BPC-157 is not a known teratogen in the way that isotretinoin or thalidomide are, but the absence of teratogenicity data is not the same as demonstrated safety. Women of reproductive age using BPC-157 should use reliable contraception and discuss discontinuation at least one menstrual cycle before any planned conception attempt. This is a precautionary recommendation in the absence of safety data, not an evidence-based washout period.

Who This Is Right For, and Who Should Pause

Women Who Might Consider Discussing BPC-157 With a Provider

• Women with chronic tendinopathy or post-surgical recovery who have not responded to standard physiotherapy and nutrition optimization.
• Women with inflammatory bowel conditions who have exhausted approved treatment options and are working with a gastroenterologist.
• Post-menopausal women with connective tissue concerns, after ruling out estrogen deficiency as the primary driver.

Women Who Should Not Use BPC-157

• Anyone who is pregnant, trying to conceive, or breastfeeding.
• Women with active autoimmune disease who are not under close specialist supervision.
• Women taking immunosuppressant medications, given the theoretical immune-modulating effects and the complete absence of drug-interaction data.
• Anyone sourcing the product from an unvetted online vendor without a Certificate of Analysis from an accredited third-party lab.
• Women with a history of hormone-sensitive cancers. BPC-157 has proposed growth-factor-modulating activity, and its effects on tumor microenvironments have not been studied in humans.

If You Decide to Proceed: Minimum Safety Steps in Maryland

If you have weighed the evidence and the legal situation and choose to pursue BPC-157, these are the minimum steps that reduce your risk.

Find a licensed Maryland prescriber who will supervise your use. This means a physician, nurse practitioner, or physician assistant who will take a history, review your medications, and monitor your response. A provider who sells peptides without a clinical evaluation is not practicing medicine; they are running a retail operation.

Request a Certificate of Analysis (COA). A COA from an accredited third-party laboratory should confirm peptide identity, concentration (expressed as a percentage of label claim), sterility, and absence of heavy metals and microbial contamination. Do not accept a COA issued by the manufacturer itself. USP <797> standards apply to sterile compounded preparations and set minimum requirements for beyond-use dating and sterility testing.

Start with the lowest available dose and document your cycle day. Because no female-specific pharmacokinetic data exists, beginning at the lower end of the dose ranges described in animal studies and translated to human weight (commonly cited as 250 to 500 mcg per injection in clinical settings, though this has no RCT basis) and tracking your response across your menstrual cycle gives you the most information.

Report adverse effects. You can file a MedWatch report directly with the FDA even for products that are not FDA-approved. This data contributes to the evidence base that women deserve.

What Maryland Women Actually Ask About BPC-157